Last reviewed · How we verify
gefitinib combined with chemotherapy
gefitinib combined with chemotherapy is a Small molecule drug developed by Qilu Pharmaceutical Co., Ltd.. It is currently in Phase 2 development. Also known as: yiruike.
At a glance
| Generic name | gefitinib combined with chemotherapy |
|---|---|
| Also known as | yiruike |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma (PHASE2)
- Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer (PHASE2)
- Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma (NA)
- A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) (PHASE1, PHASE2)
- Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) (PHASE1, PHASE2)
- High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NA)
- Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer (PHASE3)
- A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gefitinib combined with chemotherapy CI brief — competitive landscape report
- gefitinib combined with chemotherapy updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about gefitinib combined with chemotherapy
What is gefitinib combined with chemotherapy?
gefitinib combined with chemotherapy is a Small molecule drug developed by Qilu Pharmaceutical Co., Ltd..
Who makes gefitinib combined with chemotherapy?
gefitinib combined with chemotherapy is developed by Qilu Pharmaceutical Co., Ltd. (see full Qilu Pharmaceutical Co., Ltd. pipeline at /company/qilu-pharmaceutical-co-ltd).
Is gefitinib combined with chemotherapy also known as anything else?
gefitinib combined with chemotherapy is also known as yiruike.
What development phase is gefitinib combined with chemotherapy in?
gefitinib combined with chemotherapy is in Phase 2.
Related
- Manufacturer: Qilu Pharmaceutical Co., Ltd. — full pipeline
- Also known as: yiruike
- Compare: gefitinib combined with chemotherapy vs similar drugs
- Pricing: gefitinib combined with chemotherapy cost, discount & access